Washington Notebook

WASHINGTON - FDA last week unveiled a final rule on geriatric labeling of prescription drugs and biologics, nearly seven years after the agency first proposed regulations to establish a "precautions" subsection of the label on the use of drugs in elderly or geriatric patients.

The agency said the delay in drafting a final rule was caused by industry concerns that compliance with the original draft rule would be too expensive and time consuming. The final draft has been modified, principally by allowing an extended period for updating labeling